HOB BIOTECH(SH:688656) Xin Lang Cai Jing·2025-09-12 08:56Group 1 - The core viewpoint of the news is that Haobo Biopharmaceutical Co., Ltd. has seen a significant increase in its stock price, rising 5.46% on September 12, with a total market capitalization of 9.808 billion yuan and a cumulative increase of 12.93% over four consecutive days [1] - Haobo's main business involves the research, production, and sales of in vitro diagnostic reagents, with reagent sales accounting for 89.46% of its revenue, other sales at 5.86%, instrument sales at 3.84%, and rental sales at 0.85% [1] - The company is located in Suzhou Industrial Park and was established on June 8, 2009, with its listing date on January 13, 2021 [1] Group 2 - From the perspective of major fund holdings, one fund under Nuoan Fund has heavily invested in Haobo, with Nuoan Jingxin Mixed Fund holding 17,100 shares, representing 5.9% of the fund's net value, making it the third-largest holding [2] - The fund has seen a floating profit of approximately 137,100 yuan today and a total floating profit of 287,300 yuan during the four-day increase [2] - Nuoan Jingxin Mixed Fund was established on December 8, 2015, with a current scale of 39.4081 million yuan and has achieved a year-to-date return of 41.35% [2]